| Literature DB >> 32578859 |
Anders Holt1, Gunnar H Gislason1,2, Morten Schou1, Bochra Zareini1, Tor Biering-Sørensen1, Matthew Phelps2, Kristian Kragholm3,4, Charlotte Andersson5, Emil L Fosbøl6, Morten Lock Hansen1, Thomas A Gerds2,7, Lars Køber6,8, Christian Torp-Pedersen9, Morten Lamberts1.
Abstract
AIM: To determine the incidence, patient characteristics, and related events associated with new-onset atrial fibrillation (AF) during a national COVID-19 lockdown. METHODS ANDEntities:
Keywords: Atrial fibrillation; COVID-19 pandemic; Collateral damage; National lockdown
Mesh:
Year: 2020 PMID: 32578859 PMCID: PMC7337750 DOI: 10.1093/eurheartj/ehaa494
Source DB: PubMed Journal: Eur Heart J ISSN: 0195-668X Impact factor: 29.983
Take home figureIncidence of new-onset atrial fibrillation and related ischaemic stroke and death during the first 3 months of 2019 and 2020. (A and B) Incidence rates of new-onset atrial fibrillation (AF) within the first 3 months of 2019 and 2020 including hospitalizations. Incidence rates per 1000 person-years are read on the left y-axis. The black line shows the proportion of AF diagnoses with a related event (ischaemic stroke or all-cause death within 7 days of AF diagnosis); the dotted line shows the proportion among hospitalized patients with new-onset AF. Proportions in % are read on the right y-axis.
Characteristics of patients with new-onset atrial fibrillation from a 3-week national lockdown and three corresponding weeks in the previous year
| Characteristics | 12–18 March 2019 ( | 19–25 March 2019 ( | 26 March–1 April 2019 ( | 12–18 March 2020 ( | 19–25 March 2020 ( | 26 March–1 April 2020 ( | 12 March–1 April 2019 ( | 12 March–1 April 2020 ( |
|
|---|---|---|---|---|---|---|---|---|---|
| Age, median [IQR] | 76 [67, 82] | 74 [67, 82] | 74 [67, 80] | 73 [65, 80] | 73 [65, 80] | 74.5 [67, 80] | 75 [67, 81] | 74 [66, 80] | 0.014 |
| Male, | 202 (57.4) | 193 (56.8) | 212 (58.7) | 147 (63.4) | 115 (63.2) | 83 (56.1) | 607 (57.6) | 345 (61.4) | 0.16 |
| Type of AF diagnosis, | 0.06 | ||||||||
| Primary | 239 (67.9) | 220 (64.7) | 255 (70.6) | 149 (64.2) | 109 (59.9) | 96 (64.9) | 714 (67.8) | 354 (63.0) | |
| Secondary | 113 (32.1) | 120 (35.3) | 106 (29.4) | 83 (35.8) | 73 (40.1) | 52 (35.1) | 339 (32.2) | 208 (37.0) | |
| CHA2DS2-VASc, | 0.048 | ||||||||
| Score = 0 | 48 (13.6) | 50 (14.7) | 56 (15.5) | 39 (16.8) | 29 (15.9) | 28 (18.9) | 154 (14.6) | 96 (17.1) | |
| Score = 1 | 29 (8.2) | 38 (11.2) | 41 (11.4) | 30 (12.9) | 32 (17.6) | 13 (8.8) | 108 (10.3) | 75 (13.3) | |
| Score ≥2 | 275 (78.1) | 252 (74.1) | 264 (73.1) | 163 (70.3) | 121 (66.5) | 107 (72.3) | 791 (75.1) | 391 (69.6) | |
| Educational level, | 0.14 | ||||||||
| Basic or high school | 269 (76.4) | 267 (78.5) | 283 (78.4) | 184 (79.3) | 133 (73.1) | 101 (68.2) | 819 (77.8) | 418 (74.4) | |
| Higher education | 83 (23.6) | 73 (21.5) | 78 (21.6) | 48 (20.7) | 49 (26.9) | 47 (31.8) | 234 (22.2) | 144 (25.6) | |
| Comorbidity, | |||||||||
| Vascular disease | 31 (8.8) | 34 (10.0) | 36 (10.0) | 33 (14.2) | 27 (14.8) | 14 (9.5) | 101 (9.6) | 74 (13.2) | 0.034 |
| Cancer | 35 (9.9) | 28 (8.2) | 29 (8.0) | 33 (14.2) | 32 (17.6) | 24 (16.2) | 92 (8.7) | 89 (15.8) | <0.001 |
| Stroke | 24 (6.8) | 28 (8.2) | 27 (7.5) | 18 (7.8) | 13 (7.1) | 12 (8.1) | 79 (7.5) | 43 (7.7) | 0.99 |
| Heart failure | 13 (3.7) | 10 (2.9) | 16 (4.4) | 19 (8.2) | 12 (6.6) | 9 (6.1) | 39 (3.7) | 40 (7.1) | 0.004 |
| Diabetes mellitus | 19 (5.4) | 20 (5.9) | 22 (6.1) | 25 (10.8) | 10 (5.5) | 11 (7.4) | 61 (5.8) | 46 (8.2) | 0.08 |
| Hypertension | 172 (48.9) | 153 (45.0) | 177 (49.0) | 104 (44.8) | 76 (41.8) | 66 (44.6) | 502 (47.7) | 246 (43.8) | 0.15 |
| Chronic kidney disease | 9 (2.6) | 13 (3.8) | 8 (2.2) | 9 (3.9) | 3 (1.6) | 5 (3.4) | 30 (2.8) | 17 (3.0) | 0.96 |
| COPD | 16 (4.5) | 32 (9.4) | 14 (3.9) | 18 (7.8) | 12 (6.6) | 9 (6.1) | 62 (5.9) | 39 (6.9) | 0.47 |
| Gastrointestinal bleeding | 10 (2.8) | 16 (4.7) | 10 (2.8) | 6 (2.6) | <3 | 5 (3.4) | 36 (3.4) | 13 (2.3) | 0.28 |
| Hospital setting, | <0.0001 | ||||||||
| Outpatient | 127 (36.1) | 125 (36.8) | 148 (41.0) | 72 (31.0) | 41 (22.5) | 50 (33.8) | 400 (38.0) | 163 (29.0) | |
| Hospitalized | 219 (62.2) | 202 (59.4) | 208 (57.6) | 138 (59.5) | 112 (61.5) | 79 (53.4) | 629 (59.7) | 329 (58.5) | |
| Virtual contact | 6 (1.7) | 13 (3.8) | 5 (1.4) | 22 (9.5) | 29 (15.9) | 19 (12.8) | 24 (2.3) | 70 (12.5) | |
| Outcomes, | |||||||||
| Related event | 23 (6.5) | 23 (6.8) | 13 (3.6) | 13 (5.6) | 15 (8.2) | 16 (10.8) | 59 (5.6) | 44 (7.8) | 0.10 |
| Stroke | 18 (5.1) | 17 (5.0) | 10 (2.8) | 11 (4.7) | 8 (4.4) | 10 (6.8) | 45 (4.3) | 30 (5.3) | 0.40 |
| All-cause death | 5 (1.4) | 6 (1.8) | 3 (0.8) | <3 | 7 (3.8) | 6 (4.1) | 14 (1.3) | 15 (2.7) | 0.08 |
Dark grey, lockdown period 2020 (from 12 March to 1 April); Light grey, reference period 2019.
IQR, interquartile range; COPD, chronic obstructive pulmonary disease.
P-values referring to the comparison of the combined 3 weeks of lockdown with the three corresponding weeks in 2019.
The term vascular disease covers both ischaemic heart disease and peripheral artery disease.
No physical contact, but a hospital contact with a physician, e.g. via phone or video call.
Related event refers to ischaemic stroke 1 week before or 1 week after first-time AF diagnosis, the latter including death from all causes.